AgomAb Therapeutics (AGMB) Competitors

$12.50 +0.40 (+3.31%)

As of 04:00 PM Eastern

AGMB vs. NTLA, DMRA, IMTX, MBX, and BCAX

Should you be buying AgomAb Therapeutics stock or one of its competitors? The main competitors of AgomAb Therapeutics include Intellia Therapeutics (NTLA), Damora Therapeutics, Inc. Common Stock (DMRA), Immatics (IMTX), MBX Biosciences (MBX), and Bicara Therapeutics (BCAX). These companies are all part of the "pharmaceutical products" industry.

How does AgomAb Therapeutics compare to Intellia Therapeutics?

AgomAb Therapeutics (NASDAQ:AGMB) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

: In the previous week, Intellia Therapeutics had 15 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 16 mentions for Intellia Therapeutics and 1 mentions for AgomAb Therapeutics. Intellia Therapeutics' average media sentiment score of 0.48 beat AgomAb Therapeutics' score of 0.00 indicating that Intellia Therapeutics is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AgomAb Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Intellia Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: AgomAb Therapeutics has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -609.85%. AgomAb Therapeutics' return on equity of 0.00% beat Intellia Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
AgomAb Therapeutics N/A N/A N/A
Intellia Therapeutics -609.85% -56.81% -45.34%
: AgomAb Therapeutics currently has a consensus target price of $32.00, suggesting a potential upside of 156.00%. Intellia Therapeutics has a consensus target price of $20.09, suggesting a potential upside of 50.92%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe AgomAb Therapeutics is more favorable than Intellia Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AgomAb Therapeutics
0 Sell rating(s)
1 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.75
Intellia Therapeutics
3 Sell rating(s)

10 Hold rating(s)

9 Buy rating(s)

1 Strong Buy rating(s)
2.35
: 88.8% of Intellia Therapeutics shares are held by institutional investors. 3.1% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
: AgomAb Therapeutics has higher earnings, but lower revenue than Intellia Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AgomAb Therapeutics N/A N/A N/A N/A N/A
Intellia Therapeutics $67.67M 23.24 -$412.69M -$3.83 N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Intellia Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Intellia Therapeutics	-609.85%	-56.81%	-45.34%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	N/A	N/A	N/A
Intellia Therapeutics	$67.67M	23.24	-$412.69M	-$3.83	N/A

Summary

Intellia Therapeutics beats AgomAb Therapeutics on 7 of the 12 factors compared between the two stocks.

How does AgomAb Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

AgomAb Therapeutics (NASDAQ:AGMB) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

: In the previous week, Damora Therapeutics, Inc. Common Stock had 2 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 3 mentions for Damora Therapeutics, Inc. Common Stock and 1 mentions for AgomAb Therapeutics. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 1.02 beat AgomAb Therapeutics' score of 0.00 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AgomAb Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Damora Therapeutics, Inc. Common Stock
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: AgomAb Therapeutics' return on equity of 0.00% beat Damora Therapeutics, Inc. Common Stock's return on equity.
Company Net Margins Return on Equity Return on Assets
AgomAb Therapeutics N/A N/A N/A
Damora Therapeutics, Inc. Common Stock N/A -147.05% -279.49%
: AgomAb Therapeutics currently has a consensus target price of $32.00, suggesting a potential upside of 156.00%. Damora Therapeutics, Inc. Common Stock has a consensus target price of $43.40, suggesting a potential upside of 74.51%. Given AgomAb Therapeutics' higher probable upside, equities research analysts clearly believe AgomAb Therapeutics is more favorable than Damora Therapeutics, Inc. Common Stock.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AgomAb Therapeutics
0 Sell rating(s)
1 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.75
Damora Therapeutics, Inc. Common Stock
1 Sell rating(s)

1 Hold rating(s)

4 Buy rating(s)

2 Strong Buy rating(s)
2.88
: 14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. 10.5% of Damora Therapeutics, Inc. Common Stock shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AgomAb Therapeutics N/A N/A N/A N/A N/A
Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$12.10 N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Damora Therapeutics, Inc. Common Stock	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Damora Therapeutics, Inc. Common Stock	N/A	-147.05%	-279.49%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	N/A	N/A	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$12.10	N/A

Summary

Damora Therapeutics, Inc. Common Stock beats AgomAb Therapeutics on 7 of the 10 factors compared between the two stocks.

How does AgomAb Therapeutics compare to Immatics?

Immatics (NASDAQ:IMTX) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

: Immatics currently has a consensus target price of $19.00, indicating a potential upside of 73.52%. AgomAb Therapeutics has a consensus target price of $32.00, indicating a potential upside of 156.00%. Given AgomAb Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe AgomAb Therapeutics is more favorable than Immatics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immatics
1 Sell rating(s)
1 Hold rating(s)

7 Buy rating(s)

0 Strong Buy rating(s)
2.67
AgomAb Therapeutics
0 Sell rating(s)

1 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.75
: AgomAb Therapeutics has lower revenue, but higher earnings than Immatics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Immatics $48.27M 30.42 -$222.26M -$1.84 N/A
AgomAb Therapeutics N/A N/A N/A N/A N/A
: In the previous week, Immatics had 2 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 3 mentions for Immatics and 1 mentions for AgomAb Therapeutics. AgomAb Therapeutics' average media sentiment score of 0.00 beat Immatics' score of -0.25 indicating that AgomAb Therapeutics is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immatics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
AgomAb Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: 64.4% of Immatics shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
: AgomAb Therapeutics has a net margin of 0.00% compared to Immatics' net margin of -411.90%. AgomAb Therapeutics' return on equity of 0.00% beat Immatics' return on equity.
Company Net Margins Return on Equity Return on Assets
Immatics -411.90% -41.81% -34.72%
AgomAb Therapeutics N/A N/A N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$48.27M	30.42	-$222.26M	-$1.84	N/A
AgomAb Therapeutics	N/A	N/A	N/A	N/A	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immatics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
AgomAb Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-411.90%	-41.81%	-34.72%
AgomAb Therapeutics	N/A	N/A	N/A

Summary

AgomAb Therapeutics beats Immatics on 6 of the 10 factors compared between the two stocks.

How does AgomAb Therapeutics compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap manufacturing companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MBX Biosciences N/A N/A -$86.97M -$2.41 N/A
AgomAb Therapeutics N/A N/A N/A N/A N/A
: In the previous week, AgomAb Therapeutics had 1 more articles in the media than MBX Biosciences. MarketBeat recorded 1 mentions for AgomAb Therapeutics and 0 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 0.00 equaled AgomAb Therapeutics'average media sentiment score.
Company Overall Sentiment
MBX Biosciences Neutral
AgomAb Therapeutics Neutral
: MBX Biosciences currently has a consensus target price of $53.25, indicating a potential upside of 79.90%. AgomAb Therapeutics has a consensus target price of $32.00, indicating a potential upside of 156.00%. Given AgomAb Therapeutics' higher possible upside, analysts plainly believe AgomAb Therapeutics is more favorable than MBX Biosciences.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MBX Biosciences
2 Sell rating(s)
0 Hold rating(s)

9 Buy rating(s)

1 Strong Buy rating(s)
2.75
AgomAb Therapeutics
0 Sell rating(s)

1 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.75
: AgomAb Therapeutics' return on equity of 0.00% beat MBX Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
MBX Biosciences N/A -28.72% -27.55%
AgomAb Therapeutics N/A N/A N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A
AgomAb Therapeutics	N/A	N/A	N/A	N/A	N/A

Company	Overall Sentiment
MBX Biosciences	Neutral
AgomAb Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-28.72%	-27.55%
AgomAb Therapeutics	N/A	N/A	N/A

Summary

AgomAb Therapeutics beats MBX Biosciences on 4 of the 6 factors compared between the two stocks.

How does AgomAb Therapeutics compare to Bicara Therapeutics?

Bicara Therapeutics (NASDAQ:BCAX) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bicara Therapeutics N/A N/A -$137.95M -$2.53 N/A
AgomAb Therapeutics N/A N/A N/A N/A N/A
: In the previous week, Bicara Therapeutics had 3 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 4 mentions for Bicara Therapeutics and 1 mentions for AgomAb Therapeutics. AgomAb Therapeutics' average media sentiment score of 0.00 beat Bicara Therapeutics' score of -0.04 indicating that AgomAb Therapeutics is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bicara Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
AgomAb Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Bicara Therapeutics currently has a consensus price target of $28.00, indicating a potential upside of 20.90%. AgomAb Therapeutics has a consensus price target of $32.00, indicating a potential upside of 156.00%. Given AgomAb Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe AgomAb Therapeutics is more favorable than Bicara Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bicara Therapeutics
1 Sell rating(s)
3 Hold rating(s)

8 Buy rating(s)

0 Strong Buy rating(s)
2.58
AgomAb Therapeutics
0 Sell rating(s)

1 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.75
: AgomAb Therapeutics' return on equity of 0.00% beat Bicara Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Bicara Therapeutics N/A -32.49% -30.87%
AgomAb Therapeutics N/A N/A N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.53	N/A
AgomAb Therapeutics	N/A	N/A	N/A	N/A	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicara Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AgomAb Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Company	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	-32.49%	-30.87%
AgomAb Therapeutics	N/A	N/A	N/A

Summary

AgomAb Therapeutics beats Bicara Therapeutics on 5 of the 7 factors compared between the two stocks.

Get AgomAb Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AGMB vs. The Competition

Export

Metric	AgomAb Therapeutics	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$452.96M	$362.87M	$4.21B	$11.87B
Dividend Yield	N/A	N/A	5.61%	5.21%
P/E Ratio	N/A	N/A	23.40	28.47
Price / Sales	N/A	372.54	186.69	60.92
Price / Cash	N/A	N/A	52.82	36.52
Price / Book	N/A	2.81	38.31	6.67
Net Income	N/A	-$81.71M	$114.66M	$332.53M
7 Day Performance	17.48%	6.50%	1.23%	2.01%
1 Month Performance	16.60%	5.53%	5.54%	9.19%
1 Year Performance	N/A	N/A	18.68%	39.59%

AgomAb Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AGMB AgomAb Therapeutics	N/A	$12.50 +3.3%	$32.00 +156.0%	N/A	$452.96M	N/A	N/A	62	News Coverage
NTLA Intellia Therapeutics	2.8208 of 5 stars	$13.20 +1.2%	$20.09 +52.2%	N/A	$1.54B	$67.67M	N/A	600	Analyst Revision High Trading Volume
DMRA Damora Therapeutics, Inc. Common Stock	2.8181 of 5 stars	$24.23 -5.0%	$43.40 +79.1%	N/A	$1.54B	N/A	N/A	40	Positive News Gap Down
IMTX Immatics	2.149 of 5 stars	$11.59 +2.1%	$19.00 +63.9%	N/A	$1.52B	$54.60M	N/A	260	Upcoming Earnings Analyst Downgrade
MBX MBX Biosciences	2.3707 of 5 stars	$29.04 -9.2%	$53.25 +83.4%	N/A	$1.52B	N/A	N/A	N/A	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AGMB) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AgomAb Therapeutics (AGMB) Competitors

AGMB vs. NTLA, DMRA, IMTX, MBX, and BCAX

How does AgomAb Therapeutics compare to Intellia Therapeutics?

Summary

How does AgomAb Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does AgomAb Therapeutics compare to Immatics?

Summary

How does AgomAb Therapeutics compare to MBX Biosciences?

Summary

How does AgomAb Therapeutics compare to Bicara Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGMB vs. The Competition

AgomAb Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AgomAb Therapeutics (AGMB) Competitors

AGMB vs. NTLA, DMRA, IMTX, MBX, and BCAX

How does AgomAb Therapeutics compare to Intellia Therapeutics?

Summary

How does AgomAb Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does AgomAb Therapeutics compare to Immatics?

Summary

How does AgomAb Therapeutics compare to MBX Biosciences?

Summary

How does AgomAb Therapeutics compare to Bicara Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGMB vs. The Competition

AgomAb Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools